Clinical OMICS

JUL-AUG 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1138741

Contents of this Issue

Navigation

Page 43 of 51

42 Clinical OMICs July/August 2019 www.clinicalomics.com F our-year-old liquid biopsy company Inivata, based in Cam- bridge, U.K., with a testing laboratory in Research Triangle Park, NC, is now making its presence felt in the growing circu- lating tumor DNA (ctDNA) analysis arena. The company's positive momentum is exemplified by two roughly concurrent developments this year. In late March, the company closed its Series B funding round that raised £39.8 million ($52.6 million), money that will be used primarily to support the continued commercial roll-out of its InVisionFirst-Lung liquid biopsy test for non-small cell lung cancer (NSCLC). A couple of weeks later, it received a final local coverage determination for the test from Medicare administrative contractor Palmetto GBA, a decision that effectively provides nationwide Medi- care reimbursement for the test. In early June, on the heels of these developments, company CEO Clive Morris sat down with Clinical OMICs Editor in Chief Chris Anderson at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago to discuss the company's progress and its vision for the future. How was Inivata founded? Morris: We are a spinout from the University of Cambridge in the U.K. Our testing platform was specifically developed for circulating tumor DNA and the challenges of it. Because the levels of circulating tumor DNA are very low in some patients, you need an exquisitely sensitive, specific test. Rather than adapting technologies that have been used somewhere else that are less than ideal, what (Nitzan Rosenfeld) our scientific founder did was create technology that is designed to be and is, we have shown, as sensitive as digital droplet PCR, which Clive Morris CEO, Inivata IN CONVERSATION WITH

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JUL-AUG 2019